The venous thromboembolic risk and the clot wave analysis: A useful relationship?

Clinical Chemistry and Laboratory Medicine

Volumn 56, Issue 3, 2018, Pages 448-453

  Ruberto, Maria Filomena ^a   Marongiu, Francesco ^a   Mandas, Antonella ^a   Mameli, Antonella ^a   Porru, Mariagrazia ^a   Cianchetti, Elisabetta ^a   Barcellona, Doris ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

aPTT derivatives; clot wave analysis; D Dimer; fibrinogen; internal medicine ward; Padua Prediction Score

Indexed keywords

D DIMER; FIBRINOGEN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

ACCELERATION; ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADOLESCENT; ADULT; AGED; ANALYSIS; ARTICLE; BLOOD CLOTTING; CLOT WAVE ANALYSIS; CONTROLLED STUDY; DENSITY; EMBOLISM PREVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VELOCITY; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING TEST; MIDDLE AGED; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 85037850801     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2017-0678     Document Type: Article

References (20)

1. Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008;141:587-97.
2. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e195S-226.
3. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8:2450-57.
4. Braun PJ, Givens TB, Stead AG, Beck LR, Gooch SA, Swan RJ, et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997;78:1079-87.
5. Solano C, Zerafa P, Bird R. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. Int J Lab Hematol 2011;33:67-78.
6. Shima M, Thachil J, Nair SC, Srivastava A, Scientific and standardization committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013;11:1417-20.
7. Lance MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015;13:1.
8. Siegemund T, Scholz U, Schobess R, Siegemund A. Clot waveform analysis in patients with haemophilia A. Haemostaseologie Supplement 2014;34:S48-62.
9. Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost 2013;11:467-73.
10. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998;80:65-9.
11. Ruberto MF, Sorbello O, Civolani A, Barcellona D, Demelia L, Marongiu F. Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena. Int J Lab Hematol 2017;39:369-74.
12. Olson JD. D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem 2015;69:1-46.
13. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thromb Haemost 2010;104:92-9.
14. Marongiu F, Conti M, Mameli G, Murtas ML, Balzano S, Sorano G, et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988;11:723-5.
15. Marongiu F, Conti M, Mameli G, Sorano GG, Cirillo R, Balestrieri A. "Falsely increased" B beta 15-42 levels in diabetes. Diabetes Care 1990;13:1129-30.
16. Marongiu F, Mameli G, Acca MR, Mulas G, Medda A, Tronci MB, et al. Fibrinopeptide A and B beta 15-42 in liver cirrhosis. Haemostasis 1988;18:126-28.
17. Marongiu F, Biondi G, Conti M, Murtas ML, Mameli G, Sorano GG, et al. Is a hypercoagulable state present in hypothyroidism? Thromb Haemost 1992;67:729.
18. Palareti G. D-Dimer testing in patients with a first unprovoked venous thromboembolism. Ann Intern Med 2015;162:670-71.
19. Bjori E, Johnsen HS, Hansen JB, Braekkan SK. D-dimer at venous thrombosis diagnosis is associated with risk of recurrence. J Thromb Haemost 2017;15:917-24.
20. Chatterjee MS, Denney WS, Jing H, Diamond SL. Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. PLoS Comput Biol 2010; doi: 10.1371/journal.pcbi.1000950.